Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$37.91 USD
+0.03 (0.08%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $37.92 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
For Royalty Pharma PLC, the company has a dividend yield of 2.32% compared to the Medical - Biomedical and Genetics industry's median yield of zero percent.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RPRX 37.91 +0.03(0.08%)
Will RPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Other News for RPRX
Royalty Pharma Reports Second Quarter 2025 Results | RPRX Stock News
Royalty Pharma reports Q2 portfolio receipts of $727M
Earnings Scheduled For August 6, 2025
Royalty Pharma Q2 2025 Earnings Preview
Here are the major earnings before the open Wednesday